Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer
Michael Engsig, Chief Executive Officer of Nykode Therapeutics, stated: “The decision to focus on locally advanced cervical cancer and recurrent metastatic head and neck, and discontinue the C-04 trial in 2L cervical cancer, is part of our strategic repositioning to concentrate resources on the most commercially promising areas where we create significant benefits for patients in need, while generating value for shareholders. We remain highly enthusiastic about the broad potential of VB10.16 to make a meaningful difference in the lives of patients with HPV-driven cancers. While we regret the impact of excluding 2L cervical cancer from our immediate pipeline, we are eager to advance VB10.16 where we see the highest likelihood of clinical efficacy and the greatest market potential.
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
